Skip to Content
Merck
  • Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry).

Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry).

Circulation journal : official journal of the Japanese Circulation Society (2013-03-19)
Naoki Sato, Katsuya Kajimoto, Takehiko Keida, Masayuki Mizuno, Yuichiro Minami, Dai Yumino, Kuniya Asai, Koji Murai, Ryo Muanakata, Toshiyuki Aokage, Yasushi Sakata, Kyoichi Mizuno, Teruo Takano
ABSTRACT

Hospitalized heart failure (HHF) is a critical issue in Japan. To improve its management and outcomes, the clinical features, in-hospital management, and outcomes should be analyzed to improve the guidelines for HHF. The acute decompensated heart failure syndromes (ATTEND) registry is the largest study of HHF in Japan. The present report covers the clinical features and in-hospital management of HHF patients. The data from 4,842 enrolled patients have demonstrated that most Japanese HHF patients are elderly, with new onset, and a history of hypertension and orthopnea on admission. During hospitalization, furosemide and carperitide were commonly used and the length of stay was extremely long (mean 30 days), with 6.4% in-hospital mortality. The findings of the present study suggest the following: (1) the focus for hypertensive elderly and diabetic patients should be on primary prevention of HHF,(2) more intensive management with noninvasive positive pressure ventilation should be performed at the urgent stage, (3) it is necessary to clarify the clinical benefit of carperitide and angiotensin-receptor blockers, because they are commonly used in Japan, and (4) it is necessary to clarify the relationship between in-hospital mortality and length of stay from the viewpoint of both outcome and cost of patient care.

MATERIALS
Product Number
Brand
Product Description

Furosemide, European Pharmacopoeia (EP) Reference Standard
Supelco
Furosemide, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Furosemide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Furosemide